Celcuity Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. The audited financial statements cover 2020 and 2019.
Business context
Celcuity is a clinical-stage biotechnology company developing CELsignia companion diagnostic tests. Its platform analyzes signaling activity in living tumor cells to identify cancer subtypes and potential matches for targeted therapies. The company had not generated revenue through year-end 2020 and remained focused on research, test development, and clinical collaborations.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.68 million | $6.27 million |
| General and administrative expense | $1.87 million | $1.54 million |
| Total operating expenses / operating loss | $9.56 million | $7.81 million |
| Net loss | $9.47 million | $7.36 million |
| Net loss per share, basic and diluted | $0.92 | $0.72 |
| Net cash used in operating activities | $7.15 million | $6.00 million |
| Cash and cash equivalents at year-end | $11.64 million | $18.74 million |
There was no revenue or gross margin to report. Cash declined by $7.10 million during 2020. Total assets were $12.96 million, total liabilities $1.25 million, and stockholders’ equity $11.70 million at year-end. Liabilities included operating lease liabilities of $248,379 and finance lease liabilities of $14,109; the filing reports no material conventional debt balance. Management believed cash on hand would fund the current operating plan and obligations for at least 12 months from the report’s issuance. The company also had an ATM program permitting up to $10 million in share sales; 17,725 shares generated approximately $183,000 gross proceeds in 2020.
Changes from the prior year
- Net loss increased $2.11 million, or 29%, as operating expenses rose 22% to $9.56 million.
- R&D expense increased 23%, primarily from compensation and clinical validation and laboratory work; G&A increased 22%, including higher compensation and public-company costs.
- Operating cash use increased from $6.00 million to $7.15 million. Year-end cash fell from $18.74 million to $11.64 million; 2019 investing cash inflow included proceeds from sales of investments, while 2020 investing cash use was primarily property and equipment purchases.
- Interest income fell 82% to $82,109, primarily due to lower market interest rates.
Outlook, milestones, and risks
- Management expected continued significant R&D and G&A spending and anticipated increased commercial spending as commercialization efforts develop. The filing provides no specific revenue, earnings, or other quantitative financial guidance.
- The company completed development of an ovarian cancer test in 2020 and continued development of a RAS-signaling test. It reported four clinical-trial collaborations involving Genentech/NSABP, Puma/West Cancer Center, Puma/Massachusetts General Hospital and other cancer centers, and Pfizer/Sarah Cannon Research Institute.
- COVID-19-related enrollment constraints delayed expected interim results from the FACT-1 and FACT-2 trials to the fourth quarter of 2021 or first quarter of 2022, with final results expected about nine months later. Enrollment in FACT-3 and FACT-4 was expected to begin in the second quarter of 2021; timelines remained subject to enrollment and other trial risks.
- Key risks include failure to demonstrate clinical utility, delays or negative trial results, difficulty securing pharmaceutical partners, uncertain adoption and reimbursement, potential changes to LDT regulation, competition, and the need for additional capital. The company’s sole testing laboratory is in Minneapolis, and it had no redundant facility.
- The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting at December 31, 2020; the auditor did not attest to internal controls because Celcuity was an emerging growth company.
Important facts for investors to verify
- Whether trial enrollment and results track the stated timelines, and whether trial outcomes support the proposed diagnostic-treatment matches.
- Cash burn, remaining liquidity, and whether additional equity or other financing will be needed; the reported runway is management’s estimate.
- Any revenue-generating partnerships, milestone payments, test sales, reimbursement coverage, or commercial launch plans, since the company had no revenue through year-end 2020.
- Regulatory status of CELsignia tests, including any FDA requirements for LDTs or companion diagnostics.
- Potential dilution from the ATM facility, outstanding options and warrants, and future equity issuances.